Glenmark Pharma on Thursday said it has received final approval from the USFDA to manufacture and market Potassium Chloride extended release capsules and oral contraceptive Norethindrone Acetate and Ethinyl Estradiol tablets in the American market.
“Glenmark Pharmaceuticals Inc has been granted final approval by the US Food and Drug Administration (US FDA) for Potassium Chloride extended release capsules USP, 10mEq, of Actavis laboratories Fl, Inc,” the company said in a BSE filing. Quoting IMS data, Glenmark Pharma said the approved product has an estimated market size of $74.1 million for the 12 months ended November 2015.